ERBB2 and gastroesophageal junction adenocarcinoma: Notably, based on the findings of the KEYNOTE-811 study, the FDA has approved pembrolizumab plus trastuzumab and chemotherapy as a first-line treatment for HER2-positive locally advanced or metastatic G/GEJ adenocarcinoma [11].